Eligibility for the Medicare GLP-1 Bridge will also be limited to Medicare beneficiaries who have not filled a prescription under their Part D plan for a GLP-1 in 2026, and who do not have a diagnosis with a condition that is a medically accepted indication for a GLP-1 drug that could be covered under Part D (specified by CMS as type 2 diabetes, obstructive sleep apnea (OSA), and noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH)), even if they otherwise meet the clinical criteria
Time to treat the climate and nature crisis as one indivisible global health emergency
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years
For thyroid patients, this personalized approach reduces guesswork and optimizes the likelihood of safe, effective weight loss without destabilizing thyroid management
Never start with a larger dose
Particularly with a name like the Barbie peptide, melanotan may seem low stakes, but doctors stress thats not the case at all